Merck temporarily suspends Zilmax in U.S., Canada
SUMMIT, N.J. -- Merck Animal Health, in conjunction with independent experts, will conduct a scientific audit, which will monitor the process of feeding of Zilmax, and will follow identified cattle from the feedyard to the packing plant to determine potential causes of lameness and other mobility issues during feeding, transportation, offloading, and staging at the processing facility. According to an August Merck Animal Health press release, Merck will do a thorough review of potential compounding factors -- such as nutrition, transportation, and receiving facilities.
In support of its customers and to ensure effective implementation of its five-step approach to ensuring responsible beef, Merck has made the decision to temporarily suspend sales of Zilmax in the United States and Canada. This will allow sufficient time for the establishment of valid study protocols, identification of feeders and packers to participate in the audit, and creation of a third-party team to oversee this process and validate its results.
In addition, Merck will also accelerate the development of its Merck Animal Health Advisory Board, which will bring together industry experts, producers, academics, and company leadership to promote an open dialogue on animal well-being and help shape and strengthen the company’s animal health and well-being program in the future.
Zilmax sales in the United States and Canada were $159 million in 2012. Visit the Zilmax Information Center at http://www.merck-animal-health.com/zilmaxinfocenter.aspx for more details and updates on Zilmax.